4.7 Article

Ovatodiolide sensitizes aggressive breast cancer cells to doxorubicin, eliminates their cancer stem cell-like phenotype, and reduces doxorubicin-associated toxicity

期刊

CANCER LETTERS
卷 364, 期 2, 页码 125-134

出版社

ELSEVIER IRELAND LTD
DOI: 10.1016/j.canlet.2015.05.006

关键词

Doxorubicin; Ovatodiolide; TNBC; Breast cancer; Drug toxicity; Cancer stem cell

类别

资金

  1. National Science Council of Taiwan [MOST103-2325-B-038-002]
  2. Taipei Medical University-Shuang Ho Hospital [100TMU-SHH-07, 101TMU-SHH-04]

向作者/读者索取更多资源

Triple-negative breast cancer (TNBC) is chemotherapy refractory and associated with poor clinical prognosis. Doxorubicin (Doxo), a class I anthracycline and first-line anticancer agent, effective against a wide spectrum of neoplasms including breast carcinoma, is associated with several cumulative dose-dependent adverse effects, including cardiomyopathy, typhilitis, and acute myelotoxicity. This study evaluated the usability of Ovatodiolide (Ova) in sensitizing TNBC cells to Doxo cytotoxicity, so as to reduce Doxo effective dose and consequently its adverse effects. TNBC cell lines MDA-MB-231 and HS578T were used. Pre-treatment of the TNBC cells with 10 mu M Ova 24 h before Doxo administration increased the Doxo anticancer effect (IC50 1.4 mu M) compared to simultaneous treatment with Doxo (IC50 1.8 mu M), or Doxo alone (IC50 9.2 mu M). Intracellular accumulation of Doxo was lowest in Ova pre-treated cells at all Doxo concentrations, when compared with Doxo or simultaneously treated cells. In comparison to the Doxo-only group, cell cycle analysis of MDA-MB-231 cells treated concurrently with 2.5 mu M Ova and 1.25 mu M Doxo showed increased percentage of cells arrested at G0/G1; however, pre-treatment with the same concentration of Ova 24 h before Doxo showed greater tumor growth inhibition, with a 2.4-fold increased percentage of cells in G(0)/G(1) arrest, greater Doxo-induced apoptosis, and significantly reduced intracellular Doxo accumulation. Additionally, Ova-sensitized TNBC cells also lost their cancer stem cell-like phenotype evidenced by significant dissolution, necrosis of formed mammospheres. Taken together, these findings indicate that Ova sensitizes TNBC cells to Doxo and potentiates doxorubicin-induced elimination of the TNBC cancer stem cell-like phenotype. (C) 2015 Elsevier Ireland Ltd. All rights reserved.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据